Central Venous Catheter Consideration in Pediatric Oncology: A Systematic Review and Meta-analysis From the American Pediatric Surgical Association Cancer Committee
Topic overview
Systematic review of tunneled central venous catheter practices in pediatric oncology found no significant difference in complication rates by catheter composition. Limited evidence suggests platelet counts <30,000/mcL may increase hematoma risk and neutropenia (ANC<500) may slightly increase infection risk, but high-quality data to guide catheter placement and management remain lacking.
Key takeaways
- Catheter material (silicone vs polyurethane) does not significantly affect complication rates including fracture, thrombosis, or infection.
- Platelet counts ≥30,000/mcL appear safe for CVC placement; counts <30,000/mcL may carry small increased hematoma risk.
- Neutropenia (ANC <500) may slightly increase CLABSI risk, but evidence is limited and placement is often still appropriate.
- Catheter removal remains standard for complicated/persistent CLABSI; lock therapy shows promise for salvage but lacks robust data.
- Despite 15,000+ annual pediatric oncology CVCs in North America, high-quality evidence guiding placement and management is severely lacking.
Comments